{"nctId":"NCT03425656","briefTitle":"Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer","startDateStruct":{"date":"2016-07-09","type":"ACTUAL"},"conditions":["Malignant Neoplasm of Breast"],"count":108,"armGroups":[{"label":"Trastuzumab (AryoTrust)","type":"EXPERIMENTAL","interventionNames":["Drug: Trastuzumab plus docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide"]},{"label":"Trastuzumab (Herceptin)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Trastuzumab plus docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide"]}],"interventions":[{"name":"Trastuzumab plus docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 18-70 years old female patients\n* Patients with newly diagnosed stage III (locally advanced) or inoperable stage II (due to sizes larger than 5 cm or high tumor to breast ratio) tumors are candidates for participation.\n* Willing and able to sign an informed consent\n* Pathological diagnosis of adenocarcinoma of the breast\n* ECOG status of 0-1\n* With any ER/PR status\n* HER2 positive (Immunohistochemical (IHC) 3+ intensity, amplification of the HER2 gene on fluorescence in situ hybridization (FISH+ ) or HER2 positive results of Chromogenic in situ hybridization (CISH+)).\n\nExclusion Criteria:\n\n* Clinical or radiologic evidence of metastatic disease\n* History of any other malignancy including previous breast cancer, second non-breast malignant disease\n* History of previous chemotherapy\n* Left ventricular ejection fraction \\[LVEF\\] \\<55% confirmed by echo cardiogram within 3 months before registration, Any prior myocardial infarction, History of documented congestive heart failure (CHF),Any prior history of arrhythmia or cardiac valvular disease requiring medications or clinically significant, Current use of medications for treatment of angina pectoris, Current uncontrolled hypertension (diastolic \\> 100 mmHg or systolic \\> 200 mmHg), A severe conduction abnormality (having pacemaker or diagnosed by the ECG) and any other significant cardiovascular disease.\n* Hematologic abnormalities including baseline Absolute Neutrophil Count (ANC) of ≤1,500/µL or platelet count ≤ 100,000/µL\n* Liver dysfunction including : (baseline)\n\n  * Alanine amino transferase (ALT) and/or aspartate amino transferase (AST) ≥ 3 Upper Limit Normal (ULN)\n  * Alkaline phosphatase (ALP) ≥3 ͯ ULN\n  * serum total bilirubin \\> 1.5 ULN\n* Renal dysfunction, defined as serum creatinine ≥2.5 mg/dL\n* Pregnant, lactating women or women of childbearing potential who are not willing to use adequate contraception","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pathologic Complete Response","description":"the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Objective Response","description":"clinical Complete Response + clinical Partial Response","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"Breast Conservation Rate","description":"Patients who underwent lumpectomy","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety Assessment by Evaluation of Adverse Events (AEs) and Abnormal Laboratory Results","description":"Safety assessment, including the incidence of all reported AEs and abnormal laboratory results was done. All AEs were classified based on the Medical Dictionary for Regulatory Activities (MedDRA Desktop Browser 4.0 Beta) terms as System Organ Class (SOC) and Preferred Term (PT). All the reported events were graded according to the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0). Moreover, seriousness of AEs was assessed according to International Council for Harmonization (ICH-E2B) guidelines. The causality relation was assessed based on the World Health Organization (WHO) criteria.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Participants With Anti-drug Antibodies Against Trastuzumab (AryoTrust)","description":"The levels of anti-drug antibodies against Trastuzumab ( aryotrust ) are assessed via ELISA and the percantage of positive value are reported","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":54},"commonTop":["Alopecia","Anaemia","Alanine aminotransferase increased","Neutropenia","Aspartate aminotransferase increased"]}}}